181 related articles for article (PubMed ID: 32931337)
21. Transient Outward K
Choi BR; Li W; Terentyev D; Kabakov AY; Zhong M; Rees CM; Terentyeva R; Kim TY; Qu Z; Peng X; Karma A; Koren G
Circ Arrhythm Electrophysiol; 2018 Jun; 11(6):e005414. PubMed ID: 29769222
[TBL] [Abstract][Full Text] [Related]
22. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
[TBL] [Abstract][Full Text] [Related]
23. In the RyR2(R4496C) mouse model of CPVT, β-adrenergic stimulation induces Ca waves by increasing SR Ca content and not by decreasing the threshold for Ca waves.
Kashimura T; Briston SJ; Trafford AW; Napolitano C; Priori SG; Eisner DA; Venetucci LA
Circ Res; 2010 Dec; 107(12):1483-9. PubMed ID: 20966392
[TBL] [Abstract][Full Text] [Related]
24. Modest reductions of cardiac calsequestrin increase sarcoplasmic reticulum Ca2+ leak independent of luminal Ca2+ and trigger ventricular arrhythmias in mice.
Chopra N; Kannankeril PJ; Yang T; Hlaing T; Holinstat I; Ettensohn K; Pfeifer K; Akin B; Jones LR; Franzini-Armstrong C; Knollmann BC
Circ Res; 2007 Sep; 101(6):617-26. PubMed ID: 17656677
[TBL] [Abstract][Full Text] [Related]
25. Remodeling of repolarization and arrhythmia susceptibility in a myosin-binding protein C knockout mouse model.
Toib A; Zhang C; Borghetti G; Zhang X; Wallner M; Yang Y; Troupes CD; Kubo H; Sharp TE; Feldsott E; Berretta RM; Zalavadia N; Trappanese DM; Harper S; Gross P; Chen X; Mohsin S; Houser SR
Am J Physiol Heart Circ Physiol; 2017 Sep; 313(3):H620-H630. PubMed ID: 28646025
[TBL] [Abstract][Full Text] [Related]
26. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
[TBL] [Abstract][Full Text] [Related]
27. R4496C RyR2 mutation impairs atrial and ventricular contractility.
Ferrantini C; Coppini R; Scellini B; Ferrara C; Pioner JM; Mazzoni L; Priori S; Cerbai E; Tesi C; Poggesi C
J Gen Physiol; 2016 Jan; 147(1):39-52. PubMed ID: 26666913
[TBL] [Abstract][Full Text] [Related]
28. Transgenic upregulation of IK1 in the mouse heart is proarrhythmic.
Piao L; Li J; McLerie M; Lopatin AN
Basic Res Cardiol; 2007 Sep; 102(5):416-28. PubMed ID: 17546530
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor 21 inhibited ischemic arrhythmias via targeting miR-143/EGR1 axis.
Li J; Xu C; Liu Y; Li Y; Du S; Zhang R; Sun Y; Zhang R; Wang Y; Xue H; Ni S; Asiya M; Xue G; Li Y; Shi L; Li D; Pan Z; Zhang Y; Wang Z; Cai B; Wang N; Yang B
Basic Res Cardiol; 2020 Jan; 115(2):9. PubMed ID: 31900593
[TBL] [Abstract][Full Text] [Related]
30. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K
PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621
[TBL] [Abstract][Full Text] [Related]
31. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
Shan J; Xie W; Betzenhauser M; Reiken S; Chen BX; Wronska A; Marks AR
Circ Res; 2012 Aug; 111(6):708-17. PubMed ID: 22828895
[TBL] [Abstract][Full Text] [Related]
32. Reduced expression of cardiac ryanodine receptor protects against stress-induced ventricular tachyarrhythmia, but increases the susceptibility to cardiac alternans.
Zhong X; Vallmitjana A; Sun B; Xiao Z; Guo W; Wei J; Ni M; Chen Y; O'Brien ER; Gillis AM; Hoshijima M; Takeshima H; Hove-Madsen L; Benitez R; Belke D; Wayne Chen SR
Biochem J; 2018 Jan; 475(1):169-183. PubMed ID: 29170159
[TBL] [Abstract][Full Text] [Related]
33. Functional consequences of stably expressing a mutant calsequestrin (CASQ2D307H) in the CASQ2 null background.
Kalyanasundaram A; Viatchenko-Karpinski S; Belevych AE; Lacombe VA; Hwang HS; Knollmann BC; Gyorke S; Periasamy M
Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H253-61. PubMed ID: 21984545
[TBL] [Abstract][Full Text] [Related]
34. Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry.
Barajas-Martinez H; Hu D; Ontiveros G; Caceres G; Desai M; Burashnikov E; Scaglione J; Antzelevitch C
Circ Cardiovasc Genet; 2011 Feb; 4(1):51-7. PubMed ID: 21148745
[TBL] [Abstract][Full Text] [Related]
35. Calsequestrin mutation and catecholaminergic polymorphic ventricular tachycardia: a simulation study of cellular mechanism.
Faber GM; Rudy Y
Cardiovasc Res; 2007 Jul; 75(1):79-88. PubMed ID: 17531962
[TBL] [Abstract][Full Text] [Related]
36. Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function.
Zhao YT; Valdivia CR; Gurrola GB; Powers PP; Willis BC; Moss RL; Jalife J; Valdivia HH
Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1669-77. PubMed ID: 25775566
[TBL] [Abstract][Full Text] [Related]
37. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model.
Liu N; Colombi B; Memmi M; Zissimopoulos S; Rizzi N; Negri S; Imbriani M; Napolitano C; Lai FA; Priori SG
Circ Res; 2006 Aug; 99(3):292-8. PubMed ID: 16825580
[TBL] [Abstract][Full Text] [Related]
38. Mutation-linked, excessively tight interaction between the calmodulin binding domain and the C-terminal domain of the cardiac ryanodine receptor as a novel cause of catecholaminergic polymorphic ventricular tachycardia.
Nishimura S; Yamamoto T; Nakamura Y; Kohno M; Hamada Y; Sufu Y; Fukui G; Nanno T; Ishiguchi H; Kato T; Xu X; Ono M; Oda T; Okuda S; Kobayashi S; Yano M
Heart Rhythm; 2018 Jun; 15(6):905-914. PubMed ID: 29427818
[TBL] [Abstract][Full Text] [Related]
39. Characterization of inwardly rectifying K+ channel in human cardiac myocytes. Alterations in channel behavior in myocytes isolated from patients with idiopathic dilated cardiomyopathy.
Koumi S; Backer CL; Arentzen CE
Circulation; 1995 Jul; 92(2):164-74. PubMed ID: 7600647
[TBL] [Abstract][Full Text] [Related]
40. Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model.
Kobayashi S; Yano M; Uchinoumi H; Suetomi T; Susa T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Yamamoto T; Matsuzaki M
Circ J; 2010 Nov; 74(12):2579-84. PubMed ID: 20944434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
